Testing a new drug to help reduce methamphetamine use
Official title: Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2
Funded at Myosin Therapeutics INC. · NIH-11168308 · Data updated 2026-11-12
This study is testing a new treatment called MT-110 to see if it can help people with methamphetamine use disorder stay off the drug by reducing cravings and the urge to use again.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Myosin Therapeutics INC. NIH-funded |
| Lab location | 1 site (Jupiter, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,496,586 |
| NIH project number | 1R44DA063266-01 |
| Project ID | NIH-11168308 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with methamphetamine use disorder.
✕Less likely to help
Patients who are not struggling with methamphetamine use disorder or those under 21 years old may not benefit from this research.
What this research studies
This research investigates the effectiveness of a novel therapeutic agent called MT-110 in reducing methamphetamine use among individuals with methamphetamine use disorder (MUD). The study aims to evaluate how this drug can help maintain abstinence by targeting relapse triggers that often lead to a return to drug use. Participants will receive a single intravenous dose of MT-110, and the research will assess its impact on reducing cravings and drug-seeking behavior. The approach is based on preclinical findings that suggest MT-110 can restore brain function affected by methamphetamine use.
Why it matters
Potential benefit: If successful, this research could provide a new pharmacotherapy option for individuals struggling with methamphetamine addiction, potentially leading to better long-term recovery outcomes.
How similar studies have gone: Previous research has shown promise in using pharmacological approaches to treat addiction, but this specific drug and its mechanism are novel and have not been widely tested in humans.
Where this research is happening
-
Myosin Therapeutics INC.
Jupiter, United States Active
Researchers
- Principal investigator: Young, Erica J — Myosin Therapeutics INC.
- Study coordinator: Young, Erica J
Related research
Other NIH-funded projects on the same topics.
-
MT-125: a brain-penetrant treatment to slow glioblastoma spread and growth
A new drug, MT-125, taken by people with recurrent glioblastoma, targets two motor proteins to slow cancer spread and growth inside the brain.
-
MT-125 treatment for recurrent high-grade brain tumors
Adults with recurrent high-grade gliomas will receive the brain-penetrant drug MT-125 to find safe doses and check whether it can slow tumor invasion and growth.
-
New treatment for aggressive brain cancer glioblastoma
This study is testing a new treatment called MT-125 for glioblastoma, a tough type of brain cancer, to see if it can help stop the cancer from growing and spreading, with the hope of improving survival for patients.
-
Developing a new medication to help prevent relapse in methamphetamine users
This study is testing a new medication called MT-110 to help people with methamphetamine use disorder stay off the drug and avoid relapse, since there aren't any approved treatments available right now.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.